Earnings ·
Pliant Therapeutics reported second quarter 2026 financial results with a net loss of $22.4 million, compared to $43.3…
PLRXPliant Therapeutics, Inc.
Pliant Therapeutics reported second quarter 2026 financial results with a net loss of $22.4 million, compared to $43.3 million in the prior-year period. Research and development expenses decreased to $16.7 million from $32.2 million due to the termination of the bexotegrast IPF program and reduced headcount. General and administrative expenses fell to $7.1 million from $13.4 million, also driven by lower personnel costs. The company ended the quarter with $159.6 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into late 2028. Clinically, enrollment in the FORTIFY Phase 1b trial for PLN-101095 remains strong and ahead of schedule, with interim data expected in 2027. The board appointed Flavia Borellini and Robert Iannone to enhance oncology expertise. Pliant Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics.